Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images
NCT ID: NCT05960188
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2023-03-01
2023-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Radiologists will look at each case for up to five seconds and offer an opinion (on a 1-10 scale) about how sure they are that a case is normal. Next, they will see the opinion of the AI. Finally, they will say (using a 1-10) scale, how willing they would be for the AI to triage this case without human intervention.
This study is the start of an effort to understand the conditions under which radiologists might be willing to declare a case "normal" with little or no human examination.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening Mammogram
NCT00535678
Test of Digital Breast Tomosynthesis vs. Regular Mammography in Detecting Breast Cancer in Women Undergoing Diagnostic Mammography
NCT00535327
The Added Value of DBT Over Mammography in Local Tumor Staging in Patients With BIRADS 4 or 5 Lesions
NCT06854887
Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast Biopsy
NCT00535184
Prospective Chart-Review: Impact of Combination - Digital Breast Tomosynthesis + Digital Mammography
NCT01593384
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The core idea of Project 1 is that it might be possible for Os to reliably eliminate a set of cases in screening mammography after just a brief look at a 2D image or, potentially, after an AI system takes a brief look at the image. That is, the clinician and/or the AI would look at the image and know "for sure" there is nothing there and would be willing to dismiss or "triage" the case on the basis of this brief look. If the reader was not completely sure, the case would get more scrutiny.
As a start at looking at this issue, the investigators wanted to estimate how willing clinicians would be to triage a case and how they would interact with an AI that was asked to triage cases. A challenge for any implementation of triage will be to get clinicians (to say nothing of lawyers, et al) to accept the idea of not looking at an image/case or of looking briefly at, say, the 2D image and being willing not to look at the 3D digital tomosynthesis (DBT) images. The experiment the investigators report here is intended to be a start on studying this issue. There is a continuum of cases from "obviously normal" to "obviously abnormal". The investigators wanted to estimate the point on that continuum below which a case is so normal, that readers would be willing to let the computer triage the case and/or would be willing to triage a case themselves. It is also possible that there are cases so abnormal that the patients can be recalled for further examination by the computer alone though the investigators are not studying that form of triage in this case. The investigators hypothesize that these triage points will be related to both the computer's rating of normality and the reader's rating.
Method: A bilateral 2D mammogram is presented for 5 seconds. The time limit is intended to limit the normal scrutiny that a radiologist would give to the case. The investigators want a decision based on the "gist" of the case. To mimic the low prevalence of disease in a screening mammography, only 4 of 150 cases are positive. Readers are told that the cases mimic a screening setting so they know that positive cases will be rare, but they are not told the actual prevalence.
The investigators ask radiologists to answer two questions about each of up to 150 single image "cases". ("Up to 150" because radiologists can and do quit at without completing all cases. Using a rating scale method, the investigators ask:
1. How sure are participants that these images are from a normal case?
Next the investigators tell readers that "The computer rated these images as X out of 10 (10: highest probability of cancer present)." This AI value is a real rating of abnormality, generated by Transpara version 1.7.0 which returns a probability of malignancy score for the examination. The ratings were obtained by Sarah Verboom of Radboud U.
Then the investigators ask the investigators asked if the reader would think that it was reasonable for the computer to triage the case without further human inspection.
2. How willing would participants be for the computer to make the decision about this case alone without having participants look at it?
Os answered using a sliding bar that served as a rating scale. The selected rating was displayed on top of the sliding bar.
Participants:
The first observers for this study were tested at a 'pop-lab', organized at the European Conference of Radiology (ECR, Vienna, March 2023). The investigators have been organizing these labs as an opportunity for researchers from many labs to come to big meetings like ECR where they might be able to test radiologists in larger numbers than at home. The upside is access to readers. The downside is that the investigators can typically get only 15-30 min of a reader's time. Thus, the readers for this experiment were a population of convenience. The investigators tested 15 readers. These varied widely in experience. The investigators asked how many screening cases they estimated that they read each year. This varied from 0 (students who had learned about mammography but were not in practice) to 8000. Readers also varied in how many cases they were willing to read for us, before running out of time/patience. The range was 19 to 148 (avg 83 cases). At this stage, the investigators are underpowered to say with any conviction if these variables have an important impact of the results. This is a chronic problem with testing experts like radiologists. It is extremely difficult to collect as much data as one would wish. Nevertheless, these data can give us information about the factors that will determine the success or failure of image triage.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AI Opinion
For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* some experience reading mammography.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeremy M Wolfe, PhD
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Visual Attention Lab / Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007P000646-D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.